Technical Analysis for CBLI - Cleveland BioLabs, Inc.

Grade Last Price % Change Price Change
grade F 0.6602 -10.78% -0.08
CBLI closed down 10.78 percent on Friday, December 6, 2019, on 11 percent of normal volume. It ran into resistance at its 50 day moving average.

Trend Table & Recent Signals

ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical CBLI trend table...

Date Alert Name Type % Chg
50 DMA Resistance Bearish 0.00%
Fell Below 20 DMA Bearish 0.00%
180 Bearish Setup Bearish Swing Setup 0.00%
1,2,3 Pullback Bullish Bullish Swing Setup 0.00%
Outside Day Range Expansion 0.00%
Wide Bands Range Expansion 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Down 5 Days in a Row Weakness 0.00%
1,2,3 Pullback Bullish Bullish Swing Setup -10.78%

Older signals for CBLI ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

Cleveland BioLabs, Inc., a clinical-stage biotechnology company, engages in the research, development, and commercialization of products that have the potential to treat cancer, reduce death from total body irradiation, and counteract the genotoxic effects of radio- and chemotherapies for oncology patients. Its lead drug is Entolimod, which is being developed for radiation countermeasure and cancer treatment. The company's products candidates also include CBL0102, which is undergoing a Phase I safety and tolerability study in patients with liver metastases of solid tumors of epithelial origin, or primary advanced hepatic carcinoma; and CBL0137, which is in multi-center, single agent, dose escalation Phase I study of the oral formulation in subjects with advanced solid tumors. In addition, it has pre-clinical stage products candidates, such as CBLB612, an inducer and mobilizer of hematopoietic stem cells; Revercom, a cancer drug candidate comprising a liposome-packaged proprietary small molecule named Reversan; Mobilan, a nanoparticle-formulated recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand, flagellin; Arkil, a prospective treatment for prostate cancer; Antimycon, a proprietary small molecule lead compound generated to selectively target and inactivate oncoproteins of the Myc family; and Xenomycin family of compounds, which have a range of potential applications as antimicrobial and anti-fungal agents. The company has license agreements and collaborations with the Cleveland Clinic, Roswell Park Cancer Institute, the Children's Cancer Institute Australia, and the Armed Forces Radiobiology Research Institute. Cleveland BioLabs, Inc. was founded in 2003 and is headquartered in Buffalo, New York.
Medicine Biotechnology Cancer Clinical Medicine Treatment Of Cancer Solid Tumors Chemotherapy Stem Cells Cancer Treatments Radiation Prostate Cancer Cancer Treatment Advanced Solid Tumors

Is CBLI a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 2.16
52 Week Low 0.5
Average Volume 45,130
200-Day Moving Average 1.30
50-Day Moving Average 0.77
20-Day Moving Average 0.68
10-Day Moving Average 0.78
Average True Range 0.12
ADX 44.05
+DI 28.25
-DI 14.97
Chandelier Exit (Long, 3 ATRs ) 0.84
Chandelier Exit (Short, 3 ATRs ) 0.85
Upper Bollinger Band 0.96
Lower Bollinger Band 0.39
Percent B (%b) 0.47
BandWidth 83.93
MACD Line 0.01
MACD Signal Line -0.01
MACD Histogram 0.0153
Fundamentals Value
Market Cap 7.45 Million
Num Shares 11.3 Million
EPS -0.67
Price-to-Earnings (P/E) Ratio -0.99
Price-to-Sales 12.32
Price-to-Book 7.79
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.84
Resistance 3 (R3) 0.86 0.82 0.81
Resistance 2 (R2) 0.82 0.77 0.81 0.80
Resistance 1 (R1) 0.74 0.74 0.72 0.72 0.79
Pivot Point 0.70 0.70 0.69 0.69 0.70
Support 1 (S1) 0.62 0.65 0.60 0.60 0.53
Support 2 (S2) 0.58 0.63 0.57 0.52
Support 3 (S3) 0.50 0.58 0.51
Support 4 (S4) 0.48